Opdivo Qvantig, administered by injection in less than five minutes, is now FDA approved for solid tumor indications covered by Opdivo, a 30-minute intravenous infusion. The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. The post Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster…
While fibrates are proven to lower triglyceride levels, which can serve as a biomarker for cardiovascular disease risk, several major clinical studies from the past 20 years have failed to show a benefit of fenofibrates over and above statins in further reducing heart-related events. The post Millions are Taking a Drug that Falls Short of…
The integration of the latest technologies improves diagnostic quality and accelerates treatment solutions, decreasing the time patients spend in discomfort or pain due to dental issues. The post More than a Third of the US has Dental Anxiety. Here’s How New Technology is Improving Patient Trust appeared first on MedCity News.
This data note examines the characteristics of nursing facilities and the people living in them with data from Nursing Home Compare, a publicly available dataset that provides a snapshot of information on quality of care in each nursing facility, and CASPER (Certification and Survey Provider Enhanced Reports), a dataset that includes detailed metrics collected by…
Ampersand Biomedicines’ map of all tissue in the human body reveals “addresses,” identifying markers on disease targets that are not found on healthy tissue. The company aims to improve the targeting of biologic drugs in order to reduce on-target, off-tissue toxicity. The post Flagship’s Ampersand Bio Adds $65M to Solve One of the Top Challenges…
How does a hospital’s participation in a health plan’s Medicare Advantage (MA) provider network impact their commercial rates? Since many insurers offer both MA plans and commercial plans, there could be spillovers with respect to negotiating. How would MA network participation impact commercial rates? Marr et al. (2025) offers some hypotheses: On the one hand,…
Engaging in data sharing, observational cohort research, and deeper analysis of available data to yield further insights can drive improved results for patients, making label and cohort extension faster and more robust. The post How Real-World Data Can Support Label Extension And Safer Use Of Novel Therapies appeared first on MedCity News.
By grounding wellness programs in behavior-change science, employers can empower their people to build healthier, more sustainable habits. The post Study: Why Quick Fixes Don’t Work in Workplace Wellness appeared first on MedCity News.
By KIM BELLARD I’m starting to feel like I’m beating a dead horse, having already written a couple times recently about the Trump Administration’s attacks on science, but the hits just keep on coming. Last Friday, for example, not only did the Administration’s proposed 2026 budget slash National Science Foundation (NSF) funding by over 50%,…